Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) EPS (Weighted Average and Diluted) (2021 - 2025)

Inhibikase Therapeutics (IKT) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.14 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 78.46% to -$0.14 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.48, a 121.15% increase, with the full-year FY2024 number at -$1.16, up 63.29% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.14 for Q3 2025 at Inhibikase Therapeutics, down from -$0.11 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.88 in Q4 2024 to a low of -$1.98 in Q3 2022.
  • A 5-year average of -$0.51 and a median of -$0.46 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 1000.0% in 2022, then skyrocketed 482.61% in 2024.
  • Inhibikase Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.28 in 2021, then plummeted by 268.4% to -$1.02 in 2022, then surged by 77.45% to -$0.23 in 2023, then surged by 482.61% to $0.88 in 2024, then plummeted by 115.91% to -$0.14 in 2025.
  • Per Business Quant, the three most recent readings for IKT's EPS (Weighted Average and Diluted) are -$0.14 (Q3 2025), -$0.11 (Q2 2025), and -$0.15 (Q1 2025).